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Objectives In this study we investigate: 1) the role of multidrug resistance protein-4 (MRP4), an organic anion unidirectional
transporter, in modulating aspirin action on human platelet cyclooxygenase (COX)-1; and 2) whether the impair-
ment of aspirin–COX-1 interaction, found in coronary artery bypass grafting (CABG) patients, could be dependent
on MRP4-mediated transport.
Background Platelets of CABG patients present a reduced sensitivity to aspirin despite in vivo and in vitro drug treatment.
Aspirin is an organic anion and could be a substrate for MRP4.
Methods Intracellular aspirin concentration and drug COX-1 activity, measured by thrombin-induced thromboxane B2
(TxB2) production, were evaluated in platelets obtained from healthy volunteers (HV) and hematopoietic-
progenitor cell cultures reducing or not reducing MRP4-mediated transport. Platelet MRP4 expression was evalu-
ated, in platelets from HV and CABG patients, by dot-blot or by immunogold-electromicrographs or
immunofluorescence-microscopy analysis.
Results Inhibition of MRP4-mediated transport by dipyridamole or Mk-571 increases aspirin entrapment and its in vitro effect
on COX-1 activity (142.7  34.6 pg/108 cells vs. 343.7  169.3 pg/108 cells TxB2-production). Platelets derived
from megakaryocytes transfected with MRP4 small interfering ribonucleic acid have a higher aspirin entrapment and
drug COX-1 activity. Platelets from CABG patients showed a high expression of MRP4 whose in vitro inhibition en-
hanced aspirin effect on COX-1 (349  141 pg/108 cells vs. 1,670  646 pg/108 cells TxB2-production).
Conclusions Aspirin is a substrate for MRP4 and can be extruded from platelet through its transportation. Aspirin effect on COX-1
is little-related to MRP4-mediated aspirin transport in HV, but in CABG patients with MRP4 over-expression, its phar-
macological inhibition enhances aspirin action in an efficient way. (J Am Coll Cardiol 2011;58:752–61) © 2011 by
the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.049The ability of aspirin to act as an antiplatelet agent, reducing
cardiovascular complication in high-risk patients, is well-
documented (1). However, it was evidenced that aspirin
does not exert an equal antiplatelet action on all subjects
(2–4) and that platelet sensitivity to the inhibitory effect of
aspirin progressively decreases with time (5). Clinical and
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2011, accepted March 22, 2011.biochemical evidence support that a persistent thromboxane
A2 (TxA2) production is the most likely cause of the
residual platelet function, despite aspirin treatment. Partic-
ularly, persistent thromboxane generation predicts the risk
of the composite outcome of myocardial infarction, stroke,
See page 762
or cardiovascular death (6 – 8); patients under chronic
aspirin treatment display an interindividual variability of
TxA2 production that is functionally important in deter-
mining platelet activation (9).
Importantly, 5 days after coronary artery bypass grafting
(CABG), patients had a high incidence of transitory aspirin
resistance, due to a disturbed inhibition of platelet cyclooxy-
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August 9, 2011:752–61 Aspirin and MRP4 in Plateletsgenase (COX)-1 by aspirin (10), because a residual TxA2
production was found despite in vivo plus in vitro aspirin
treatment. The molecular mechanisms are still unclear.
Multidrug resistance protein-4 (MRP4) is a member of
the MRP/ABCC subfamily of adenosine triphosphate (ATP)-
binding cassette transporters, which are capable of pumping
a wide variety of structurally diverse endogenous and xeno-
biotic organic anions out of the cell (11). Over-expression of
MRP4 severely impaired the antiviral efficacy of nucleoside
analogs in the human T-lymphoid cell line CEM-r1 (12). It
has been recently demonstrated that human platelets express
MRP4 and drive active transport of nucleotides into dense
granules (13). Aspirin is a weak acid (pKa4.4) and can be
rapidly converted into organic anion, acetyl-salicylate, be-
coming a possible MRP4 target.
Hence, the main aim of this study was to verify whether
aspirin is a substrate for MRP4 in platelets and whether it
reduces drug activity by aspirin extrusion. Moreover, we
studied whether the impairment of aspirin–COX-1 interac-
tion, found in CABG patients, could be dependent on MRP4-
mediated transport.
Our studies were performed in platelets from healthy
volunteer (HV) human hematopoietic progenitor cell
(HPC) cultures and CABG patients.
Methods
Sources of materials. Monoclonal antibodies anti-CD34,
nti-CD61, anti-CD62, and anti-CD42b were from Becton
ickinson (Franklin Lakes, New Jersey); anti-CD41a was
rom AdB Serotec, (Kidlington, United Kingdom). Arachi-
donic acid (AA) was from Cayman-Chem (Ann Arbor,
Michigan). All nonspecified chemicals were from Sigma
Chemicals Company (St. Louis, Missouri).
Platelet preparation. Platelets were obtained from healthy
Caucasian volunteers (HV) (50% women and 50% men; age
range 25 to 58 years), who had not been taking any
medication for the previous 2 weeks; CABG patient plate-
lets were obtained both at 5 (CABG5 patients) and 10
(CABG10 patients) days after surgery (for characteristics,
see Table 1). None of the patients received additional COX
inhibitors. Informed written consent was obtained from
each patient.
Baseline Characteristics of CABG Patients (N  26)Table 1 Baseline Characteristics of CABG Patients (N  26)
Age (yrs) 55 8
Men 15 (58%)
Medications
Aspirin 100 mg/day* 26 (100%)
Calcium antagonist† 26 (100%)
ACE inhibitors/ARB† 26 (100%)
Beta-blocking agents† 26 (100%)
Statins† 26 (100%)
Values are mean  SD or n (%). *From Day 1 after surgery, previous aspirin treatment was
erminated 10 days before CABG. †From Day 2 after surgery.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary
rtery bypass graft surgery.Platelet-rich plasma and plasma-
free platelets (PFP) preparation
were obtained as previously re-
ported (9). In all experiments
platelets were resuspended to a
final concentration of 3  108/ml.
Aspirin and salicylic acid intra-
platelet concentration. The PFP
were treated with aspirin (50
mol/l; 10°C, 15 min) and then
kept at 37°C or 4°C (15 min) and
washed twice. Two of the most
efficient MRP4 inhibitors (11),
dipyridamole and MK-571 (0.1
mmol/l both), were added to the
platelet suspension before aspirin
(15 min, RT). Aspirin and sali-
cylic acid (SA) intraplatelet con-
centration was evaluated as de-
scribed (14).
Dense granules rich preparation.
Dense granules rich preparation
(DGP) was performed as de-
scribed (15). Dense granules free
preparation was performed ac-
cording to Niessen et al. (16).
After the addition of ATP (5
mmol/l) or apyrase (0.1 U/ml),
aspirin was added to the DGP
and kept either at 4°C or 37°C.
Dipyridamole or MK-571 were
added as before.
Fluo-cyclic adenosine monophos-
phate MRP4-mediated transport.
The MRP4-dependent 8-Fluo-
cyclic adenosine monophosphate
(cAMP) uptake in platelet gran-
ules was analyzed as previously de-
scribed (17). Briefly DGP was in-
cubated with 8-Fluo-cAMP,
aspirin, and SA (all 20 mol/l).
fter 10 min, DGP was washed
nd fluorescence was measured in
ictor3-fluorometer (PerkinEl-
er, Waltham, Massachusetts).
he fluorescence observed in
TP-free DGP was used as blank.
14C-acetylsalicylic acid platelet in-
corporation and secretion. After
dipyridamole treatment, the PFP
suspension was incubated with 14C-labeled aspirin (Amer-
ican Radiolabeled Chemicals, St. Louis, Missouri) for 30
min at 37°C (18). The cells were washed to remove
extra-cellular 14C-labeled aspirin.
Secretion was evaluated by measurement of the 14C-
Abbreviations
and Acronyms
AA  arachidonic acid
ATP  adenosine
triphosphate
bimane-GS  bimane-
glutathione
CABG  coronary artery
bypass grafting
CABG5  platelets
obtained 5 days after
coronary artery bypass
grafting surgery
CABG10  platelets
obtained 10 days after
coronary artery bypass
grafting surgeryc
cAMP  cyclic adenosine
monophosphate
CDCF  5-(and-6)-
carboxyl-2’,
7’-dichlorodihydrofluorescein
COX  cyclooxygenase
DGP  dense granules rich
preparation
HEK  human embryonic
kidney
HEK-ABCC4  transiently
transfected cells over-
expressing recombinant
ABCC4
HEK-Co  aspirin action in
human embryonic kidney-
293 cells
HPC  hematopoietic
progenitor cell
HV  healthy volunteers
MK  megakaryocyte
MRP4  multidrug
resistance protein-4
PDE-V  phosphodiesterase
type V
PFP  plasma-free
platelets
PGE2  prostaglandin E2
SA  salicylic acid
siRNA  small interfering
ribonucleic acid
TxA2  thromboxane A2
TxB2  thromboxane B2radioactivity in a supernatant of thrombin (0.2 U/ml)
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Aspirin and MRP4 in Platelets August 9, 2011:752–61activated PFP. The ATP released was measured with a
commercial kit (ATPlite, PerkinElmer).
Thromboxane B2 production. Thromboxane B2 (TxB2)
production, a stable TxA2 metabolite, was studied in PFP,
activated with thrombin 1 U/ml for 1 h at 37°C, and
evaluated with a commercial kit (Cayman-Chem).
Measurement of prostaglandin H synthase activity.
prostaglandin H synthase activity was performed as previ-
ously reported (19). Briefly, platelets were pre-loaded with 2
mol/l 5-(and-6)-carboxyl-2=,7=-dichlorodihydrofluorescein
CDCF) (MolecularProbes, Eugene, Oregon), which serves
s a reducing substrate for the peroxidase activities of
OX-1. The platelet COX activity was measured as AA-
nduced (5 mol/l) fluorescence enhancement in a spectro-
fluorimeter Kontron-SFM25 (Zurich, Switzerland), ther-
mostatically regulated (37°C). Nicotinamide adenine
dinucleotide phosphate oxidase inhibitor (diphenyliodo-
nium) (5 mol/l) was added to avoid reactive oxygen species
production interference. The results are reported as the rise
in CDCF fluorescence (Arbitrary Units) recorded for 1 min.
Platelet aggregation. Platelet aggregation was evaluated in
PFP with the Born method with collagen (0.5 to 10 g/ml)
as agonist (5).
HPC purification and megakaryocyte unilineage cultures.
Adult peripheral blood was obtained from HV. Low-density
mononuclear cells were isolated by Ficoll-Hypaque density-
gradient centrifugation, and CD34 HPCs were then purified
with the MiniMACS columns (Miltenyi Biotech, Paris,
France). Purified cells were more than 90% CD34, evaluated
y fluorescence-activated cell sorting analysis.
Purified HPCs (1  105 cells/ml) were grown in unilin-
age megakaryocyte (MK) liquid culture (20) for 13 days.
he cells were collected at different days of differentiation,
nd platelets—produced at the end of the culture—were
solated as reported in Guerriero et al. (21).
ransfection of small interfering ribonucleic acid. At
ay 9 of culture, differentiated MKs were seeded in antibiotic-
ree media and transfected with MRP4 small interfering
ibonucleic acid (siRNA) (160 nmol/l) (SmartPool-siRNA
uman ABCC4, Dharmacon, Chicago, Illinois) in presence of
ipofectamine 2000 (Invitrogen, Carlsbad, California). An
quivalent amount of transfection reagent (Lipofectamine
000, Invitrogen), without MRP4-siRNA, was added as mock
ontrol. After transfection the cells were reincubated in MK
iquid culture for terminal differentiation. Four days later,
ature MKs were analyzed and derived platelets were aspirin-
reated and thrombin-stimulated.
mmunoblot analysis. Platelets or cell protein extract were
repared as previously reported (22). Protein expression was
valuated by Western blot with polyclonal antibodies
gainst MRP4 (Alexis, Plymouth Meeting, Pennsylvania).
onoclonal antibody anti–beta-actin was used as control.
calar concentration of each sample has been spotted onto
itrocellulose membrane, and dot-blot analysis has been
erformed as previously reported (23), with the same
olyclonal antibody as reported in the preceding text. Theensitometric analysis was performed with the National
nstitutes of Health ImageG analyzer program.
mmunoelectron microscopy and immunofluorescence.
latelets were fixed and processed for ultrathin cryosection-
ng and immunogold labeling as previously described (24).
he primary antibody was omitted in control subjects. For
ryosection immunoelectron microscopy, platelets were la-
eled with rabbit anti-MRP4 polyclonal followed by protein
–10 nm gold (G. Posthuma and J. Slot, Utrecht, the
etherlands). For immunofluorescence, platelets were in-
ubated with anti-MRP4 polyclonal followed by FITC-
nti-rabbit (Cappel, Cochranville, Pennsylvania). In double
abeling experiments, platelets were subsequently incubated
ith anti-LAMP2 (Santa Cruz Biotechnology, Santa Cruz,
alifornia) or anti-CD42b (AlphaDiagnostic International,
an Antonio, Texas) monoclonals followed by Texas-Red-
onjugated anti-mouse (Jackson Immunoresearch Laborato-
ies, West Grove, Pennsylvania). Images at 40 and 60were
aken with an AxioCam with a Zeiss Apotome Axio Observer
1 inverted microscope (Carl Zeiss, Thornwood, New York).
easurement of MRP4 transport activity. The MRP4
ransport activity was evaluated according to Bai et al. (25),
hich takes advantage of bimane to form a fluorescent adduct
ith glutathione that is a target for MRP4. Briefly, PFP was
ncubated (6 min, 10°C) with 100 mol/l MonoChloroBi-
mane (Sigma Chemical Company) and divided into 2 aliquots;
1 was kept in ice, and 1 was incubated at 37°C (7.5 min). Both
aliquots were washed, and supernatants fluorescence was read
in a Victor3-fluorimeter (PerkinElmer). The MRP4-mediated
transport activity was expressed as the Delta bimane-
glutathione (bimane-GS) efflux between incubation at 37°C
and ice, quantified as previously reported (25).
We performed experiments with carbonylcyanidem-
chlorophenylhydrasone, 1-chloro-2,4-dinitrobenzene, and
MK571 treated platelets (25).
Prostaglandin E2 production. Arachidonic acid-induced
prostaglandin E2 (PGE2) production measured aspirin
action in human embryonic kidney (HEK)-293 cells
(HEK-Co) and in transiently transfected cells over-
expressing recombinant ABCC4 (HEK-ABCC4) accord-
ing to (26). Briefly, cells, pretreated with aspirin (100 and
200 mol/l for 30 min) were activated with AA (5 min).
The PGE2 secreted was measured by ELISA assay kit
(CaymanChem).
Statistical analysis. Results are reported as mean  SD
performed on different platelet samples. Significance was
evaluated by Student t test for paired data in in vitro
experiments and for unpaired data with unequal variance
(Welch t test) for in vivo dosages.
Results
Role of MRP4-mediated transport in human platelet
aspirin intake. To investigate whether aspirin is a substrate
and can be transported by MRP4, we used DGP, obtained
from HV human platelets, because MRP4 is predominantly
755JACC Vol. 58, No. 7, 2011 Mattiello et al.
August 9, 2011:752–61 Aspirin and MRP4 in PlateletsFigure 1 Aspirin Interaction Assay With MRP4 in DGP and Platelets
(A) Percentage of intake Fluo-cyclic adenosine monophosphate (cAMP) evaluated in dense granules rich preparation (DGP) pre-treated with aspirin, salicylic acid (SA),
and MK571. Results are the mean  SD of 4 experiments. (B) Percentage of aspirin intake in DGP. Adenosine triphosphate (ATP) at 37°C condition, assumed as con-
trol (100%). The DGP were treated at 4°C or with apyrase, dipyridamole, or MK-571. Results are shown as the mean  SD of 7 experiments. Aspirin concentration found
in DGP was 53  23 pg/mg proteins. (C, D) Percentage of 14C-aspirin and ATP release, after thrombin stimulation, from platelets labeled with 14C-aspirin (Control) or
with dipyridamole. Percentage of 14C-aspirin release versus total radioactivity intake and nmoles of ATP secreted, respectively. Mean  SD of 4 experiments. (E) Aspirin
and SA cytosolic concentration, in platelets pre-treated with dipyridamole, MK-571, or MY- 5445 or incubated at 4°C. The results were expressed as fold increase versus
aspirin-treated platelets (Control). Mean  SD of 8 experiments. Aspirin and SA concentrations found in control were 18.3  5.2 pg/109cells and 13.1  8.5
pg/109cells, respectively. (F) Thromboxane B2 (TxB2) production in aspirinated platelets dipyridamole or MK-571 pretreated or not. Mean  SEM of 4 experiments.
The TxB2 production in non-aspirinated platelets was 78,645  11,317 pg/108cells.
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Aspirin and MRP4 in Platelets August 9, 2011:752–61localized in dense granule membranes (12). To demonstrate
that aspirin is a substrate for MRP4, we used Fluo-cAMP,
a fluorimetric analog of cAMP (17). In DGP both aspirin
and SA reduced the intake of Fluo-cAMP, suggesting that
both aspirin and SA interact with MRP4 solely and specif-
ically (Fig. 1A).
To verify whether aspirin can be transported by MRP4,
its DGP intake was evaluated in the presence of ATP at
37°C and compared with that obtained by reducing active
transport (i.e., by aspirin treatments at 4°C or with an
ATP-scavenger agent, apyrase) or inhibiting MRP4 by
dipyridamole or MK-571. The results reported in Figure 1B
show that the highest aspirin entrapment in dense granules
was obtained in the presence of ATP at 37°C (control).
With incubation at 4°C or platelet pre-treatment either
apyrase or dipyridamole or Mk-571, it was observed a
reduced aspirin intake.
In dense bodies-free mixture of platelet organelles, we
found no changes in aspirin intake between 4°C and 37°C
treatment in the presence of ATP (data not shown).
After activation platelets release dense granule contents;
thus, we measured the secretion of 14C-aspirin from
thrombin-activated platelets to confirm that aspirin is able
to enter into dense granules. 14C-aspirin loaded platelets
elease the drug after thrombin activation that is markedly
educed by dipyridamole pre-treatment (Fig. 1C), whereas
TP release—analyzed to exclude nonspecific dipyridamole
ction—was unaffected (Fig. 1D).
To investigate whether aspirin can be extruded from
latelets through the MRP4-mediated transport, we mea-
ured the intracellular concentration of aspirin and SA, in
latelets pre-treated or not with MRP4 inhibitors (dipyrid-
mole or MK571). Our results showed that inhibition of
RP4-mediated transport enhanced aspirin and SA plate-
et accumulation (Fig. 1E).
To exclude that this effect could be consequent to the
nhibitory effect on phosphodiesterase type V (PDE-V), we use
nother PDE-V inhibitor, MY-5445. The results clearly dem-
nstrated that the inhibition of PDE-V has no effect on
nhancing aspirin and SA cytosolic concentrations (Fig. 1E).
Active MRP4-mediated transport requires a temperature
f 37°C for maximal efficiency. An increased aspirin and SA
ntracellular concentration was found in platelets treated at
°C, compared with treatment at 37°C (Fig. 1E). The lower
ncrease of SA concentration could be due to reduced
spirin de-acetylation at 4°C.
To evaluate the MRP4 role in aspirin-dependent platelet
OX-1 inhibition, we measured TxB2 production—a
arker of the COX-1 pathway—in aspirin-treated platelets
n the presence of MRP4 inhibitors. The TxB2 production
as lower when dipyridamole or MK-571 was added to the
latelet suspension before aspirin treatment (10, 25, and 50
mol/l), as compared with platelets treated with aspirin
alone (Fig. 1F). No statistical differences were found when
dipyridamole and Mk-571 were added after aspirin (data
not shown), thus suggesting a role of MRP4 in enhancingaspirin effect on COX-1 without any important effect on
platelet prostanoid efflux, found in other cell lines (27).
To confirm that the reduced TxB2 production induced by
dipyridamole treatment is due to enhanced aspirin action,
we performed experiments to evaluate COX-1 activity in
CDCF-loaded platelets. The results showed that the COX-
1–dependent prostaglandin H synthase activity is reduced
in platelet treated with aspirin plus dipyridamole (66.4 
15.9% of inhibition vs. untreated platelets) in comparison
with aspirin alone (49.7  17.1% of inhibition vs. untreated
platelets); no reduction was obtained when platelets were
treated with dipyridamole alone (97.6  1.9% of inhibition
vs. untreated platelets). The MK-571 was not used, because
it interferes with CDCF-fluorescence.
The reduction of TxB2 slightly decreases platelet activa-
tion; in fact, the EC50 of platelets pre-incubated with
dipyridamole or MK-571 plus aspirin (3.5 and 2.5 g/ml,
espectively) show a reduction of collagen-induced platelet
ggregation, in comparison with platelets treated with
spirin alone (1.8 g/ml).
Inhibition of MRP4 expression by siRNA transfection in
MK cultures. In our previous studies we optimized an in
vitro unilineage serum-free liquid culture system for a
virtually pure and complete MK differentiation, including
pro-platelets and platelet formation (20). To evaluate
MRP4 expression in MKs, CD34 HPCs purified from
human peripheral blood were grown in MK liquid suspen-
sion culture, and differentiated cells were analyzed by
Western blotting. The MK MRP4 expression is shown in
Figure 2, first lane.
In an effort to confirm the MRP4 involvement in aspirin
transport, we used an alternative approach of inhibition by
siRNA experiments. Differentiated MKs from liquid sus-
pension culture were transfected on day 9 with an MRP4
siRNA. Analysis of MRP4 protein expression was per-
formed 4 days after transfection. Western blot analysis
showed a strong decrease (up to 65%) of MRP4 protein
levels in siRNA-transfected cells, as compared with un-
Figure 2 MRP4 Expression in MKs
Multidrug resistance protein-4 (MRP4) expression in cultured megakaryocytes
(MKs) (Day 13) is shown in the first lane; Lipofectamine and MRP4-small inter-
fering ribonucleic acid (siRNA) transfected MKs are shown in the second and
third lanes, respectively. A representative experiment, of 3 experiments, is
presented.transfected cells treated only with Lipofectamine (Fig. 2).
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August 9, 2011:752–61 Aspirin and MRP4 in PlateletsAfter aspirin treatment, platelets derived from transfected
MKs showed both a higher aspirin entrapment and greater
aspirin effect on COX-1, in comparison with aspirin-treated
platelets obtained from untransfected MK culture. Particu-
larly, higher aspirin and SA cytosolic concentrations (1.64 
0.4-fold and 1.44  0.3-fold increase, respectively) and
ower thrombin-induced TxB2 production (73  18 pg/
08cells vs. 144  21 pg/108cells) were found in aspirinated
platelets derived from transfected MKs.
MRP4 expression in platelets from CABG patients. Our
experiments confirm an insufficient inhibition of COX-1 in
platelets of CABG5-patients under in vivo aspirin treat-
ment; in fact, TxB2 production is approximately 7,431 
3,260 pg/108cells. Additional, in vitro aspirin treatment
further reduced TxB2 production in CABG5-patient plate-
lets to a value of 1,670  646 pg/108cells (i.e., higher than
that obtained in HV platelets after the in vitro same
treatment [343.7  169.3 pg/108cells]). Thus, to verify
hether MRP4 inhibition can enhance the in vitro aspirin
fficiency in these patients, we measured TxB2 production
n CABG5-patient platelets treated in vitro with dipyrid-
mole before aspirin. This treatment significantly reduces
xB2 production from 1,670  646 pg/108cells to 349 
141 pg/108cells, thus reaching values similar to those
obtained in HV (142.7 34.6 pg/108cells). No reduction in
xB2 production relative to untreated platelets was ob-
erved with dipyridamole only (data not shown).
To investigate whether the insufficient response of the
ABG5-patients to aspirin could be correlated with MRP4
xpression, the same CABG5-patients analyzed for TxB2
roduction were studied for MRP4 expression in compari-
on with HV, with 3 different experimental approaches:
ot-blot analysis, immunoelectron microscopy, and immu-
ofluorescence.
Dot-blot analysis revealed that the MRP4 expression was
ignificantly higher in these patients, as compared with HV
Fig. 3).
Immunoelectron microscopy studies were performed to
nvestigate MRP4 intracellular distribution. In HV platelets
RP4 was mainly localized in intracellular dense granules
nd cytoplasmic vesicular elements (Fig. 4A, a), consistent
ith immunofluorescence data showing intracellular colo-
alization of MRP4 and LAMP-2 (Fig. 4B, d to f, j to l ).
n platelets from CABG5-patients (Fig. 4A, b), MRP4
taining appeared more intense and preferentially localized
t/near the plasma membrane (Fig. 4A, b and c, arrows),
hereas intracellular labeling was more disperse and mostly
ssociated with vesicular elements. These observations were
upported by double-immunofluorescence that showed
RP4 colocalizing mostly with the plasma membrane
arker CD42 and less with the delta-granules marker
AMP-2 (Fig. 4B, a to e).
The MRP4 plasma membrane transport activity has
een demonstrated, by analyzing the efflux of bimane-GS
25). In cells over-expressing MRP4 the efflux of the
imane-GS is facilitated (25). We performed experi- pents with specific inhibitors to demonstrate that, also in
latelets, the efflux of the bimane-GS is due to MRP4-
ediated transport. Platelets were treated with 1-chloro-
,4-dinitrobenzene, to limit bimane-GS adduct, or
arbonylcyanidem-chlorophenylhydrasone, to inhibit ac-
ive transport, or MK571, to reduce MRP4-mediated
ransport. In all treatments the bimane-GS efflux was
educed (Fig. 5A), demonstrating the specificity of this
ethod to study MRP4 transport activity in platelets too,
ccording to Bai et al (25).
In CABG5-patients, efflux of the bimane-GS is strongly
igher than HV (Fig. 5B).
In some patients MRP4 expression was analyzed in
latelets from the same patients—both at 5 and 10 days
fter surgery. Although MRP4 expression was quantita-
ively similar, as assessed by dot-blot assays (data not
hown), it appeared preferentially localized at the plasma
embrane in CABG5-patient platelets, compared with
hose obtained in CABG10-patient platelets (Fig. 5C, a to f).
The MRP4 plasma membrane transport activity was
educed in CABG10-patients, compared with CABG5-
atients (Fig. 5B). With regard to aspirin action, TxB2
roduction is reduced in CABG10-patient platelets (1,377 
91 pg/108cells) versus CABG5-patients. In vitro aspirin
ddition further reduced TxB2 production (462  194
Figure 3 MRP4 Expression in CABG Patients and HV
Dot-blot analysis was performed in a coronary artery bypass grafting (CABG)
patient studied and healthy volunteers (HV). (A) Representative experiment, of 3
experiments performed. (B) Densitometric analysis is reported as increasing
fold, compared with control.g/108cells). Dipyridamole treatment before aspirin addi-
p758 Mattiello et al. JACC Vol. 58, No. 7, 2011
Aspirin and MRP4 in Platelets August 9, 2011:752–61tion caused the lowest thromboxane production (266  215
g/108cells).
Finally, to confirm that MRP4 over-expression reduces
aspirin action on COX-1, we performed studies in HEK-
ABCC4 (over-expressing MRP4). The PGE2 production,
a COX-1 activation marker, is higher in HEK-ABCC4
cells than HEK-Co cells after aspirin treatment, thus
indicating that MRP4 acts as a negative regulator of aspirin
by limiting its action on COX-1 enzymes (Fig. 6). Such
PGE2 effect is not due to the higher prostaglandin secre-
tion, because MK571 treatment added after aspirin does not
induce further reduction of the PGE2 (65% vs. 63%).
Discussion
The molecular mechanisms responsible for reduced aspirin
action on COX-1 activity in CABG patients remain largely
unclear. In this study, we investigated the role of MRP4-
mediated transport in aspirin extrusion from human plate-
lets and analyzed its modulation in platelets from CABG
patients.
Our first series of experiments, performed in platelets from
HV, demonstrated the role of MRP4 as aspirin transporter.
The MRP4 is highly concentrated in platelet delta
granules (12). Therefore, we assessed that aspirin is a
substrate for MRP4 and can be transported into dense
granules. This study, carried out with DGP, provides
evidence that aspirin reduces uptake of Fluo-cAMP, fluo-
rescent substrate that is helpful in analyzing MRP4 function
and regulation, and gets into dense granules through
MRP4-mediated transport (17). The last observation was
confirmed because we obtained a release of aspirin in
thrombin-activated platelets.
Specific inhibition of MRP4 transport, such as low
temperature and MRP4 inhibitors, increases intraplatelet
entrapment of aspirin and SA. The MRP4 inhibitors
markedly reduced such aspirin release, whereas ATP secre-
tion was not affected.
The enhancement of the intraplatelet aspirin concentra-
tion, due to the MRP4 inhibitors dipyridamole or MK-571,
leads to greater aspirin efficiency. In fact, in HV, when
platelets were pre-treated with MRP4 inhibitors before
aspirin addition, TxB2 production was lower than platelets
treated with aspirin only.
The MRP4 is also a prostanoid efflux pump (27); we can
exclude that the TxB2 reduction observed is dependent on
a direct effect of MRP4-mediated thromboxane release. In
fact, only a slight reduction is observed when aspirin is
added before the MRP4 inhibitors versus aspirin alone.
Furthermore, the DCFH fluorescence, useful to study
platelet COX-1 activation, demonstrates that aspirin is
more efficient in reducing COX-1 activation in platelets
pretreated with MRP4 inhibitors. These data are in agree-
ment with a previous observation (28) showing that in vivo
treatment with the combination of dipyridamole plus aspi-Figure 4 Platelet MRP4-Localization in HV and CABG Patients
(A) MRP4 subcellular localization in platelet ultrathin cryosections from HV (a) and
CABG5 patients (b). (c, d) High magnification evidences MRP4 localization in plasma
membrane from CABG5 patient platelets. A representative experiment, of 5 experi-
ments performed. (B) Double-labeled immunofluorescence microscopy of HV (d to f,
j to l) and CABG5 patients (a to c, g to i) platelets. Platelets incubated with antibod-
ies against MRP4 (green fluorescence) or CD42b or LAMP-2 (both red fluorescence).
In c, f, i, l, colocalizing images are reported. Representative experiment, of 5 experi-
ments performed. M  mitochondria; PM  plasma membrane; other abbreviations
as in Figure 3. rin (ASAsantin) is more efficient in reducing serum-TxB2
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despite the one-half amount of aspirin present in the
combined formula. Inhibition of MRP4-mediated transport
slightly reduces aspirinated platelet activation; in fact, both
MK-571 and dipyridamole enhance collagen EC50.
Furthermore, we carried out experiments on aspirin-
treated platelets derived from cultured MKs transfected
with MRP4-siRNA. An increased aspirin and SA concen-
tration with high activity and, consequently, a lower TxB2
production was observed in platelets derived from trans-
fected MKs in comparison with their counterpart from
untransfected MKs. Therefore, the fundamental role of
MRP4 in aspirin transport is confirmed also in an in vitro
cell culture system.
A previous report (10) shows residual platelet TxB2
production in CABG5 patients that was completely
Figure 5 Platelet MRP4 Transport Activity and Localization in C
(A) Inhibition percentage of Bimane-glutathione (bimane-GS) efflux in HV platelets
drasone (CCCP), and MK571. Results are the mean  SD of 4 experiments. Cont
(B) Bimane-GS efflux from HV and CABG patient platelets. Mean  SD of fold incr
artery bypass grafting surgery (CABG5) (n  20) and platelets obtained from patie
(n  50). (C) Double-labeled immunofluorescence microscopy of CABG5 (a to c) a
fluorescence) or LAMP-2 (red fluorescence). Representative experiment, of 3. Abbrinhibited in healthy subjects (29). As a consequence ofour results, we postulated a correlation of MRP4 function
and the disturbed inhibition of platelet COX-1 by aspirin
in CABG5 patients. In agreement with Zimmermann et
al. (10), we observed that in CABG5 patients in vitro
aspirin platelet treatment is less efficient in reducing
TxB2 production. Immunoblot, immunogold, and im-
munoflorescence analysis evidenced a higher MRP4
platelet expression in CABG5 patients versus HV and,
importantly, revealed that this higher expression is par-
ticularly localized in plasma membrane. This MRP4
over-expression is also confirmed by its higher transport
activity (Bimane-GS secretion). Therefore, the high
incidence of aspirin resistance in such patients might be
ascribed to MRP4 over-expression, responsible for aspi-
rin intracellular concentration reduction and its disturbed
inhibition of COX-1. In fact, as expected, patient plate-
5- and CABG10 Patients
ated with 1-chloro-2,4-dinitrobenzene (CDNB), carbonylcyanidem-chlorophenylhy-
resents efflux of bimane-GS without inhibitors (0.87  0.12 nmol/mg protein).
f bimane-GS efflux in platelets obtained from patients 5 days after coronary
days after coronary artery bypass grafting surgery (CABG10) (n  5) versus HV
BG10 patients (d to f). Platelets incubated with antibodies against MRP4 (green
ns as in Figure 3.ABG
pre-tre
rol rep
ease o
nts 10
nd CA
eviatiolets treated in vitro with dipyridamole (MRP4-mediated
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effect on COX-1, leading to a reduced TxB2 production.
Platelets of the same CABG patients, obtained at 10 days
after surgery, are more sensitive to in vivo aspirin treatment,
according to Zimmermann et al. (10) and present reduced
MRP4 plasma membrane expression and lower transport
activity. This leads us to hypothesize that aspirin effect on
COX-1 is little related to MRP4-mediated aspirin transport
in normal conditions, but in patients with MRP4 over-
expression, its inhibition enhances aspirin action in an
efficient way.
Similarly a reduced aspirin action on COX-1 activity was
found in HEK293-ABCC4 over-expressing MRP4 (22),
versus HEK293-Co.
Conclusions
To our best knowledge, this is the first study to identify
MRP4 as a modulator of aspirin action in platelets. Our
Figure 6 Aspirin Action in HEK-ABCC4
(A) Arachidonic acid (AA)-induced prostaglandin E2 (PGE2) production in aspi-
rin-treated action in human embryonic kidney-293 cells (HEK-Co) and tran-
siently transfected cells over-expressing recombinant ABCC4 (HEK-ABCC4).
Percentage of PGE2 aspirin-dependent reduction versus non-aspirinated cells.
Mean  SD of 3 experiments. The PGE2 production by non-aspirinated HEK-Co
and HEK-ABCC4 was 7,511  2,582 pg/mg protein and 7,377  3,853
pg/mg protein, respectively. (B) Representative dot-blot performed to evaluate
MRP4 over-expression.results indicate that direct elimination of aspirin fromcytosol through MRP4-mediated transport limits drug ca-
pacity in reducing platelet function.
The MRP4 over-expression is directly linked to an
aspirin-reduced cell entrapment that leads to increased
TxB2 production, as found in CABG patients, with residual
platelet activation despite aspirin treatment. Moreover, in
vitro inhibition of MRP4-mediated transport enhances
aspirin action in platelets.
Notably, our results pave the way to further studies of the
possible correlation between MRP4 expression and a resid-
ual platelet function also in high-risk cardiovascular patients
under chronic aspirin treatment.
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